Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 61

23andMe to swallow Lemonaid for $400m

Novartis Venture Fund and Hikma Ventures are set to exit the online medical treatment provider in a cash-and-stock purchase by 23andme.

Oct 26, 2021

Click Therapeutics snaps up $52m

The digital therapeutics developer closed a series B round that included corporate venturing units and existing investors Hikma Ventures and Sanofi Ventures.

Oct 26, 2021

Egle Therapeutics lands series A funding

Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the immunotherapy developer.

Oct 26, 2021

Daily Deal Round Up: October 25, 2021

Online insurance provider Justos raised $35.8m in a SoftBank-led series A round while social game studio GreenPark Sports closed a $31m series B that included Alameda Research.

Oct 25, 2021

Xilio Therapeutics tunes into $118m IPO

Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.

Oct 25, 2021

Workit Health attracts $118m in series C

Blue Venture Fund and CVS Health Ventures helped the telemedicine system developer raise funding which will boost its expansion into new markets and expand its treatment offering.

Oct 25, 2021

Zerigo Health zeroes in on $43m

Leverage Health Solution, Cigna Ventures and Leaps by Bayer helped the skin condition treatment developer hike its total funding to approximately $67m.

Oct 25, 2021

Recode Therapeutics records $80m series B

Pfizer and Sanofi helped the precision medicine developer close a series B round which will be used to advance and expand its pipeline of respiratory disease drug candidates.

Oct 22, 2021

D&D Pharmatech decides on $51m series C

Sumitomo Mitsui’s DS Asset Management subsidiary backed the neurological and metabolic disorder drug developer in a round that will support clinical trials.

Oct 22, 2021

ShouTi shoots to $100m series B round

Eli Lilly, WuXi AppTec and Schrodinger were among the investors in the cardiovascular, pulmonary and metabolic disorder drug developer's latest round.

Oct 22, 2021
© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here